The endocytosis receptor megalin: From bench to bedside
The International Journal of Biochemistry & Cell Biology · 2023-04 · 157 · 106393
DOI: 10.1016/j.biocel.2023.106393 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The International Journal of Biochemistry & Cell Biology, 2023-04. Verfasst von Sawako Goto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Applied Molecular Medicine, Japan. Hauptthemen laut MEDLINE: Kidney Tubules, Proximal, Low Density Lipoprotein Receptor-Related Protein-2. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The large (∼600 kDa) endocytosis receptor megalin/low-density lipoprotein receptor-related protein 2 is highly expressed at the apical membrane of proximal tubular epithelial cells (PTECs). Megalin plays an important role in the endocytosis of various ligands via interactions with intracellular adaptor proteins, which mediate the trafficking of megalin in PTECs. Megalin mediates the retrieval of essential substances, including carrier-bound vitamins and elements, and impairment of the endocytic process may result in the loss of those substances. In addition, megalin reabsorbs nephrotoxic substances such as antimicrobial (colistin, vancomycin, and gentamicin) or anticancer (cisplatin) drugs and advanced glycation end product-modified or fatty acid-containing albumin. The megalin-mediated uptake of these nephrotoxic ligands causes metabolic overload in PTECs and leads to kidney injury. Blockade or suppression of the megalin-mediated endocytosis of nephrotoxic substances may represent a novel therapeutic strategy for drug-induced nephrotoxicity or metabolic kidney disease. Megalin reabsorbs urinary biomarker proteins such as albumin, α1-microglobulin, β2-microglobulin, and liver-type fatty acid-binding protein; thus, the above-mentioned megalin-targeted therapy may have an effect on the urinary excretion of these biomarkers. We have previously established a sandwich enzyme-linked immunosorbent assay to measure the ectodomain (A-megalin) and full-length (C-megalin) forms of urinary megalin using monoclonal antibodies against the amino- and carboxyl-terminals of megalin, respectively, and reported their clinical usefulness. In addition, there have been reports of patients with novel pathological anti-brush border autoantibodies targeting megalin in the kidney. Even with these breakthroughs in the characterization of megalin, a large number of issues remain to be addressed in future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Applied Molecular Medicine, Japan.
- Departments of Clinical Nutrition Science, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Niigata, Japan.
- Departments of Applied Molecular Medicine, Japan. Electronic address: akisaito@med.niigata-u.ac.jp.
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Goto, S., Hosojima, M., Kabasawa, H., & Saito, A. (2023). The endocytosis receptor megalin: From bench to bedside. The International Journal of Biochemistry & Cell Biology, 157, 106393. https://doi.org/10.1016/j.biocel.2023.106393
Vancouver
Goto S, Hosojima M, Kabasawa H, Saito A. The endocytosis receptor megalin: From bench to bedside. The International Journal of Biochemistry & Cell Biology. 2023;157:106393. doi:10.1016/j.biocel.2023.106393
BibTeX
@article{Goto2023,
author = {Goto, Sawako and Hosojima, Michihiro and Kabasawa, Hideyuki and Saito, Akihiko},
title = {The endocytosis receptor megalin: From bench to bedside},
journal = {The International Journal of Biochemistry & Cell Biology},
year = {2023},
volume = {157},
pages = {106393},
doi = {10.1016/j.biocel.2023.106393}
}
EUVIMED